Despite the promising results shown by BRAFi treatments in combination with other MAPK pathway inhibitors (EGFRi or MEKi) in BRAF-mutated metastatic colorectal cancer (mCRC), the emergence of resistance mechanisms to these drugs limits their clinical benefit. This evidence concerns the gene BRAF and metastatic colorectal cancer.